<DOC>
	<DOCNO>NCT03067831</DOCNO>
	<brief_summary>This study single arm , single center trial study safety efficacy bone marrow-derived autologous specific population stem cell mesenchymal stem cell treatment Duchenne Muscular Dystrophy ( DMD ) .</brief_summary>
	<brief_title>Bone Marrow-Derived Autologous Stem Cells Treatment Duchenne Muscular Dystrophy</brief_title>
	<detailed_description>Duchenne muscular dystrophy ( DMD ) genetically determine X-linked disease . The manifestation muscle weakness typically start around age 4-5 male deteriorate fast . Typically muscle loss occur first upper leg pelvis follow muscle upper arm . It cause mutation gene protein dystrophin . Dystrophin crucial maintain muscle fiber cell membrane . Currently , cure muscular dystrophy . Corrective surgery , brace , physical therapy may help symptom . Assisted ventilation might require patient weakness breathe muscle . Medications prescribe include steroid slow muscle degeneration , anti-convulsants control seizures muscle activity , immunosuppressant delay damage muscle cell . For decade , research conduct find effective therapy Duchenne muscular dystrophy ( DMD ) . Stem cell base therapy consider one promise method treat muscular dystrophy . Stem cell base therapy treatment Duchenne muscular dystrophy ( DMD ) proceed via two strategy . The first autologous stem cell transfer involve cell patient Duchenne muscular dystrophy ( DMD ) genetically alter vitro restore dystrophin expression subsequently re-implanted . The second allogenic stem cell transfer , contain cell individual functional dystrophin , transplant dystrophic patient . Herein , investigator describe method treatment Duchenne muscular dystrophy ( DMD ) use autologous bone marrow derive specific population stem cell mesenchymal stem cell transplant patient Duchenne muscular dystrophy ( DMD ) .</detailed_description>
	<mesh_term>Muscular Dystrophies</mesh_term>
	<mesh_term>Muscular Dystrophy , Duchenne</mesh_term>
	<criteria>Age group 325 year Duchenne muscular dystrophy diagnose basis clinical presentation Respiratory Distress Acute infection Human Immunodeficient Virus/Hepatitis B Virus/Hepatitis C Virus malignancy Acute medical condition respiratory infection , fever , hemoglobin le 8 bleeding tendency , bone marrow disorder , leave ventricular ejection fraction &lt; 30 % Pregnancy breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>25 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>stem cell</keyword>
</DOC>